Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
31studies shown
Showing 1-25 of 31
RecruitingNCT07115628

Accelerated TMS for Treatment-Resistant ECT

This study is recruiting. It focuses on depression and currently lists participation information in Belgium.

DepressionDeviceFrom 18 Years to 70 Years
Countries
Belgium
Sponsor
Universitair Ziekenhuis Brussel
Condition
Depression
RecruitingNCT05788198

Integrated Depression Care

This study is recruiting. It focuses on depression and currently lists participation information in Belgium.

DepressionOtherFrom 18 Years to 65 Years
Countries
Belgium
Sponsor
University Ghent
Condition
Depression
RecruitingNCT06966401

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study is recruiting. It focuses on depression and currently lists participation information in Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, the Netherlands, Poland, Romania, Slovakia, Sweden, the United Kingdom, and the United States.

DepressionOtherOver 18 Years
Countries
Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, Netherlands, Poland, Romania, Slovakia, Sweden, United Kingdom, United States
Sponsor
Neurocrine Biosciences
Condition
Depression
RecruitingNCT06963021

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study is recruiting. It focuses on depression and currently lists participation information in Belgium, Canada, Finland, Hungary, Latvia, the United Kingdom, and the United States.

DepressionOtherOver 18 Years
Countries
Belgium, Canada, Finland, Hungary, Latvia, United Kingdom, United States
Sponsor
Neurocrine Biosciences
Condition
Depression
RecruitingNCT05862636

Who Fares Best With Mindfulness Meditation

This study is recruiting. It focuses on depression and currently lists participation information in Belgium and the United Kingdom.

DepressionBehavioralOver 18 Years
Countries
Belgium, United Kingdom
Sponsor
Prof. dr. Filip Raes
Condition
Depression
RecruitingNCT06585787

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Argentina, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Portugal, the United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, and Ukraine.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT07084831

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Austria, Belgium, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, the Netherlands, and Spain.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Austria, Belgium, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Spain
Sponsor
European Group for Research In Schizophrenia
Condition
Schizophrenia
RecruitingNCT06126224

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, the United Kingdom, and the United States.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, the United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, and the United Kingdom.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, United Kingdom
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingISRCTN99520723

Sex differences in interoception and mental health: an investigation across the menstrual cycle

This study is recruiting. It focuses on anxiety and currently lists participation information in the United Kingdom, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.

AnxietyOtherFrom 18 Years to 40 Years
Countries
United Kingdom, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
Sponsor
University of Surrey
Condition
Anxiety
RecruitingISRCTN12329547

Trial of a digital depression management application: juli

This study is recruiting. It focuses on depression and currently lists participation information in the United Kingdom, Afghanistan, Finland, Albania, Algeria, the United States, Andorra, Angola, Antarctica, Antigua and Barbuda, Argentina, Armenia, the Netherlands, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Norway, Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cabo Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Congo, Democratic Republic, New Zealand, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Côte d'Ivoire, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini, Ethiopia, Fiji, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Vatican City, Honduras, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, North Korea, South Korea, Kosovo, Kuwait, Kyrgyzstan, Lao People's Democratic Republic, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Federated States of, Moldova, Monaco, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, North Macedonia, Oman, Pakistan, Palau, Palestine, State of, Panama, Papua New Guinea, Paraguay, Peru, the Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syria, Taiwan, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkmenistan, Tuvalu, Turkey, Uganda, Ukraine, United Arab Emirates, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, Western Sahara, Yemen, Zambia, and Zimbabwe.

DepressionOtherFrom 18 Years to 65 Years
Countries
United Kingdom, Afghanistan, Finland, Albania, Algeria, United States, Andorra, Angola, Antarctica, Antigua and Barbuda, Argentina, Armenia, Netherlands, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Norway, Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cabo Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Congo, Democratic Republic, New Zealand, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Côte d'Ivoire, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini, Ethiopia, Fiji, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Vatican City, Honduras, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, North Korea, South Korea, Kosovo, Kuwait, Kyrgyzstan, Lao People's Democratic Republic, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Federated States of, Moldova, Monaco, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, North Macedonia, Oman, Pakistan, Palau, Palestine, State of, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syria, Taiwan, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkmenistan, Tuvalu, Turkey, Uganda, Ukraine, United Arab Emirates, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, Western Sahara, Yemen, Zambia, Zimbabwe
Sponsor
University College London
Condition
Depression
RecruitingISRCTN03693000

GENome-based therapeutic drugs for DEPression

This study is recruiting. It focuses on depression and currently lists participation information in the United Kingdom, Belgium, Croatia, Denmark, Germany, Italy, Poland, and Slovenia.

DepressionOtherOver 18 Years
Countries
United Kingdom, Belgium, Croatia, Denmark, Germany, Italy, Poland, Slovenia
Sponsor
European Commission (Belgium)
Condition
Depression
RecruitingISRCTN68736636

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Israel, Italy, the Netherlands, Poland, Romania, Spain, Sweden, and Switzerland.

SchizophreniaOtherOver 18 Years
Countries
Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain, Sweden, Switzerland
Sponsor
European Group for Research in Schizophrenia (EGRIS) (Austria)
Condition
Schizophrenia
RecruitingISRCTN83240263

The MILESTONE study: improving transition from child to adult mental health care

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom, Belgium, Croatia, France, Germany, Ireland, Italy, and the Netherlands.

SchizophreniaOther
Countries
United Kingdom, Belgium, Croatia, France, Germany, Ireland, Italy, Netherlands
Sponsor
University of Warwick
Condition
Schizophrenia
Belgium | Clinical Trials | HopeStage Research